Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has been assigned a consensus recommendation of “Moderate Buy” from the eleven brokerages that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, nine have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $37.1111.

A number of brokerages have recently issued reports on TEVA. Truist Financial lifted their price target on Teva Pharmaceutical Industries from $36.00 to $38.00 and gave the stock a “buy” rating in a research note on Thursday, January 29th. Jefferies Financial Group lifted their target price on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. The Goldman Sachs Group upped their target price on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Piper Sandler raised their price target on shares of Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the stock an “overweight” rating in a research note on Monday, December 22nd. Finally, JPMorgan Chase & Co. boosted their price target on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 16th.

Teva Pharmaceutical Industries Stock Up 0.1%

TEVA stock opened at $33.96 on Tuesday. Teva Pharmaceutical Industries has a 52 week low of $12.47 and a 52 week high of $37.35. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89. The firm has a 50-day simple moving average of $32.20 and a 200-day simple moving average of $24.67. The stock has a market capitalization of $39.05 billion, a P/E ratio of 28.30, a P/E/G ratio of 1.94 and a beta of 0.70.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.31. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The company had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.36 billion. During the same period in the previous year, the firm posted $0.71 EPS. Teva Pharmaceutical Industries’s revenue was up 11.4% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Equities analysts forecast that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CAO Amir Weiss sold 12,300 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $30.20, for a total transaction of $371,460.00. Following the transaction, the chief accounting officer owned 5,650 shares in the company, valued at approximately $170,630. This trade represents a 68.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Roberto Mignone sold 77,400 shares of the business’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $30.24, for a total value of $2,340,576.00. Following the transaction, the director directly owned 367,600 shares in the company, valued at $11,116,224. This trade represents a 17.39% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 422,060 shares of company stock valued at $12,254,965. 0.55% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Harel Insurance Investments & Financial Services Ltd. increased its position in Teva Pharmaceutical Industries by 19.2% during the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 44,951,773 shares of the company’s stock worth $1,402,945,000 after purchasing an additional 7,255,083 shares during the last quarter. Phoenix Financial Ltd. grew its stake in shares of Teva Pharmaceutical Industries by 9.4% in the 3rd quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company’s stock valued at $834,164,000 after buying an additional 3,533,800 shares during the period. Menora Mivtachim Holdings LTD. increased its holdings in shares of Teva Pharmaceutical Industries by 1.1% during the 3rd quarter. Menora Mivtachim Holdings LTD. now owns 38,920,294 shares of the company’s stock worth $786,190,000 after buying an additional 427,000 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd increased its holdings in shares of Teva Pharmaceutical Industries by 18.8% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company’s stock worth $1,171,378,000 after buying an additional 5,917,423 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. raised its position in shares of Teva Pharmaceutical Industries by 14.8% during the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 37,402,212 shares of the company’s stock valued at $1,167,323,000 after buying an additional 4,820,000 shares during the period. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.